Funding opportunities
306 live opportunities from Grants.gov, NIH, NSF, and more.
Mathematics & Statistics× remove
- Assessing Toxicology Testing Practices by Medical Examiners and Coroners during the Opioid CrisisNational Institute on Drug AbusePA-25-301 closes 3/31/2029up to $636,838activenih
- Mathematical Sciences Research InstitutesU.S. National Science Foundation23-606 closes 3/14/2029postedgrants.gov
- Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional)National Institutes of HealthPAR-26-040 closes 3/5/2029postedgrants.gov
- Biomedical Technology Optimization and Dissemination Center (BTOD) (RM1 - Clinical Trial Not Allowed)National Institutes of HealthPAR-26-028 closes 1/29/2029postedgrants.gov
- SUPPORT SERVICES FOR THE PREVENTION AND TREATMENT THROUGH A COMPREHENSIVE CARE CONTINUUM FOR HIV-AFFECTED ADOLESCENTS IN RESOURCE CONSTRAINED SETTINGS IMPLEMENTATION SCIENCE NETWORKNIH Office of the Director75N94023D00001-P00007-759402300004-1 closes 8/24/2028up to $726,552activenih
- Developmental characterization of synapses between neurons and oligodendrocyte precursor cellsNational Institute of Mental HealthPA-25-150 closes 6/18/2028up to $528,000activenih
- Screening the functionality of PTEN variants and pharmacological candidates in vivoNational Institute of Mental HealthPA-21-235 closes 6/14/2028up to $464,244activenih
- Role of Two Medial Prefrontal Long-Range Recurrent Networks in Behavior Initiation and InhibitionNational Institute of Mental HealthPA-25-304 closes 6/9/2028up to $397,375activenih
- Harnessing antibody-driven bioconjugation to modulate immune functionNational Institute of Allergy and Infectious DiseasesPA-24-194 closes 5/31/2028up to $182,196activenih
- Fully recombinant, highly potent heptavalent botulinum antitoxin with ambient temperature stabilityNational Institute of Allergy and Infectious DiseasesRFA-AI-24-080 closes 5/31/2028up to $491,985activenih
- Functional Brain Signatures of Learning Disabilities Across DevelopmentEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentPA-24-194 closes 5/31/2028up to $127,926activenih
- Peptidoglycan modification activating NOD2 in N. gonorrhoeae infectionsNational Institute of Allergy and Infectious DiseasesPA-25-304 closes 5/31/2028up to $233,250activenih
- A PROTAC Strategy to Combat Botulinum NeurotoxicityNational Institute of Allergy and Infectious DiseasesPA-25-304 closes 5/31/2028up to $518,450activenih
- Next Generation pan-serotype,antitoxin for botulinum neurotoxin exposuresNational Institute of Allergy and Infectious DiseasesRFA-AI-24-080 closes 5/31/2028up to $531,688activenih
- The impact of tau on RNA and translation in progressive supranuclear palsyNational Institute on AgingPA-20-195 closes 5/31/2028up to $422,125activenih
- Prime editing therapeutics for LGMD2iEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentPA-25-304 closes 5/31/2028up to $460,625activenih
- Personalized Spatial Regulatory Networks to Decode Breast Cancer MicroenvironmentsNational Cancer InstitutePAR-25-078 closes 5/31/2028up to $178,000activenih
- Optimizing gamma-delta T cell receptor-mediated signaling to improve cancer immunotherapyNational Cancer InstitutePAR-25-078 closes 5/31/2028up to $156,000activenih
- Improved Aminopyridine Analogs for Symptomatic Treatment of BotulismNational Institute of Allergy and Infectious DiseasesRFA-AI-24-080 closes 5/31/2028up to $480,448activenih
- Transcriptomic, Genomic, and Microenvironmental Heterogeneity in pancreatic precancer: subtyping, classification, and cross-comparisonNational Cancer InstitutePAR-23-286 closes 5/31/2028up to $123,823activenih
- Proteasome Inhibitors as a Novel Drug-class for Treatment of GiardiasisNational Institute of Allergy and Infectious DiseasesPA-23-271 closes 5/31/2028up to $43,626activenih
- Uncovering genetic determinants of carbapenem resistance in Klebsiella pneumoniaeNational Institute of Allergy and Infectious DiseasesPA-25-304 closes 5/31/2028up to $480,650activenih
- Implementing a New Paradigm for Antifungal Drug DevelopmentNational Institute of Allergy and Infectious DiseasesRFA-AI-24-065 closes 5/31/2028up to $216,770activenih
- Immuno-protection and adjunctive therapeutic efficacy of nebulized pattern recognition receptor agonists in immunosuppressed mice with mold pneumoniaNational Institute of Allergy and Infectious DiseasesRFA-AI-24-065 closes 5/31/2028up to $204,964activenih
- Quantitative Predictive Dosimetry for Curative Transarterial RadioembolizationNational Cancer InstitutePAR-25-135 closes 5/31/2028up to $161,460activenih